Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.pSivida signs technology evaluation agreement with Neuron
As per the agreement, the use of pSivida’s technology as a delivery system for a treatment for dry age related macular degeneration (Dry AMD) will be evaluated. pSivida
As per the agreement, the use of pSivida’s technology as a delivery system for a treatment for dry age related macular degeneration (Dry AMD) will be evaluated. pSivida
MN-166 is used for certain neurological conditions, including progressive forms of multiple sclerosis, neuropathic pain, and drug addiction. The patent once received is expected to expire by the
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of 29 October 2012. CRTX 080 is a non-peptide, oral capsule that works by reducing
The partnership will identify important characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp technology to facilitate building an in depth understanding of the
The new AMPAKINE patents cover a series of compounds including CX2007 and CX2076, which exhibit a long duration of action and pharmacokinetic properties through August 2028. The company
The FDA had visited the Aveva manufacturing facility where ONSOLIS is produced and reported the formation of microscopic crystals and fading of the color during the 24-month shelf
Both the companies have agreed to move forward independently. As of 12 March 2012, all rights licensed to Pfizer will revert to Biocon, and all insulin distributed under
Pulmaquin is a once-a-day novel inhaled formulation consisting of a proprietary mixture of unencapsulated ciprofloxacin and ciprofloxacin encapsulated in liposomes. The formulation allows for both immediate and sustained
As per the Indian Patents Act, Natco Pharma will be able to make and sell low-cost drug in the country, through a pact with the patent holder, at
The company’s submission provides information to the FDA on Prurisol supporting a pre-IND meeting. With the meeting, Cellceutix intends for guidance to attain approval for a section 505(b)(2)